Duavee (Conjugated Estrogens/Bazedoxifene): How It Works, Who It's For, and What to Expect

Does Duavee Come in an Injectable Form? The Short Answer

Duavee has no injectable formulation. Full stop. If you searched for "Duavee self-injection technique," the answer is that there is no injection to learn. Duavee is a round, pink, film-coated oral tablet. You swallow it once daily, with or without food, at roughly the same time each day. No syringes, no needles, no refrigeration, no injection-site rotation.

This matters to clarify because some hormone therapy products used in menopause care (certain estradiol pellets placed subcutaneously, or testosterone cypionate given intramuscularly) do require injection technique guidance. Duavee is not one of them. The rest of this article explains what Duavee actually does, how it works inside your body, which women it suits best, and what the clinical trial data shows.

What Is Duavee and Why Does It Exist?

Duavee belongs to a category called a tissue-selective estrogen complex (TSEC). The FDA approved it in October 2013 for two indications in postmenopausal women who have a uterus: relief of moderate-to-severe vasomotor symptoms (hot flashes and night sweats) and prevention of postmenopausal osteoporosis. Pfizer's FDA approval package is publicly available at accessdata.fda.gov.

Before Duavee, women with an intact uterus who wanted estrogen therapy had to pair it with a progestogen to protect the uterine lining from estrogen-driven overgrowth (endometrial hyperplasia). Bazedoxifene, the second ingredient, replaces that progestogen requirement. It is a selective estrogen receptor modulator (SERM) that blocks estrogen's stimulating effects on the uterus and breast while allowing estrogen to act on the brain (reducing hot flashes), bone, and other tissues.

The Problem Duavee Was Designed to Solve

Standard combined estrogen-progestogen therapy carries a slightly elevated risk of breast cancer with longer-term use, as demonstrated in the Women's Health Initiative estrogen-plus-progestin trial. Some women, particularly those who are breast-cancer-risk-aware, prefer to avoid synthetic progestogens if there is an evidence-based alternative. Bazedoxifene's SERM properties theoretically reduce breast stimulation, which was a key design goal of the TSEC approach.

Who Manufactures It

Pfizer makes Duavee under that brand name in the United States. In Europe the same combination is marketed as Duavive. Generic versions are not currently available in the US market.

The Mechanism: How Duavee Works in Your Body

Conjugated Estrogens: The Vasomotor and Bone Component

Conjugated estrogens (CE) are a mixture of sodium estrone sulfate and other estrogens derived from the urine of pregnant mares (hence the historical acronym "Premarin," which is part of Duavee's CE component). At the 0.45 mg daily dose in Duavee, CE binds to estrogen receptors alpha and beta throughout the body. In the hypothalamus, estrogen stabilizes the thermoregulatory set point that goes haywire during menopause and triggers hot flashes. In bone, estrogen suppresses osteoclast activity, slowing the accelerated bone loss that begins in perimenopause and continues into the postmenopausal years.

Bazedoxifene: The Uterine and Breast Guard

Bazedoxifene (BZA) is the third-generation SERM in this pairing. SERMs act as estrogen receptor agonists in some tissues and antagonists in others, depending on which co-activator and co-repressor proteins are expressed locally. In the uterus and breast, BZA behaves as an antagonist. This means it blocks the endometrial proliferation that unopposed estrogen would otherwise cause, eliminating the need for a progestogen.

In bone, BZA acts as a partial agonist, adding its own bone-protective signal on top of what estrogen provides. In the hypothalamus, BZA does not block estrogen's thermoregulatory effects, allowing CE to reduce hot flashes normally.

Why This Combination Matters for Women Specifically

Women who cannot tolerate progestogens due to mood changes, bloating, or breast tenderness now have a progestogen-free oral option. Women with PCOS who reach perimenopause and menopause still require endometrial protection if they use estrogen therapy, and Duavee meets that requirement without adding a progestogen. Women with a history of progestogen-sensitive mood disorders (PMDD-like reactions to medroxyprogesterone) may find this combination more tolerable, though head-to-head mood-outcome data comparing Duavee to standard combined HRT remains limited.

The SMART Trials: What the Clinical Evidence Actually Shows

The SMART (Selective estrogens, Menopause, And Response to Therapy) program comprised five randomized, double-blind, placebo-controlled trials. Together they enrolled more than 6,000 postmenopausal women and provided the primary evidence base for Duavee's FDA approval.

SMART-1: Bone Density and Endometrial Safety

SMART-1 was a 2-year trial in approximately 3,400 women aged 40 to 75. The CE 0.45 mg / BZA 20 mg group preserved lumbar spine bone mineral density (BMD) compared to placebo (treatment difference of approximately +1.5% at the lumbar spine). Endometrial hyperplasia rates were less than 1% across all active treatment arms, comparable to placebo. This was the key demonstration that BZA provides adequate endometrial protection without a progestogen.

SMART-2: Vasomotor Symptom Efficacy

SMART-2 enrolled women with at least 7 moderate-to-severe hot flashes per day at baseline. Over 12 weeks, the CE 0.45 mg / BZA 20 mg group experienced a reduction in mean daily hot flash frequency of approximately 74% from baseline, compared to approximately 51% in the placebo group. The separation from placebo was statistically significant at week 4 and maintained through week 12.

SMART-3 and SMART-4: Sleep and Vulvovaginal Symptoms

SMART-3 showed improvements in sleep disturbance scores that correlated with hot flash reduction. SMART-4 evaluated vulvovaginal atrophy endpoints; CE/BZA improved vaginal maturation index and reduced vaginal dryness scores versus placebo, though the effect size on vulvovaginal symptoms was modest compared to local (vaginal) estrogen preparations.

SMART-5: Breast Safety Signal

SMART-5 was a 2-year mammographic density study. Mammographic density did not increase in the CE/BZA group relative to placebo, in contrast to what is seen with combined estrogen-progestogen therapy. This is a clinically meaningful finding for breast-cancer-risk monitoring, though it does not directly prove that Duavee reduces breast cancer incidence. Long-term breast cancer outcome data from a dedicated trial do not yet exist.

The WomanRx TSEC Decision Framework: When you and your prescriber are weighing Duavee against standard combined HRT, consider three factors together: your progestogen tolerance history, your baseline mammographic density (dense breasts make mammography harder to interpret, and estrogen-progestogen therapy increases density), and whether vasomotor symptom severity or bone protection is the primary driver. Women with prior PMDD-pattern reactions to progestogens and moderate-to-high baseline mammographic density are the population where Duavee's profile offers the clearest theoretical advantage over standard combined HRT.

Dosing and How to Take Duavee Correctly

The approved dose is one tablet daily: conjugated estrogens 0.45 mg / bazedoxifene 20 mg. There is no titration schedule, no dose escalation, and no lower-dose option currently approved in the United States.

Timing and Food

You can take Duavee with or without food. Taking it at the same time each day helps maintain steady plasma estrone levels. If you miss a dose, take it as soon as you remember on that same day. Do not double up the next day.

Duration of Use

The Menopause Society (formerly NAMS) recommends using hormone therapy at the lowest effective dose for the shortest duration consistent with treatment goals and individual risk. For osteoporosis prevention specifically, longer duration may be appropriate if fracture risk remains elevated and other bone therapies are not tolerated, but this requires annual shared-decision-making with your provider. Duavee's prescribing information does not specify a maximum duration, but the FDA label notes that periodic re-evaluation is warranted.

Drug Interactions Worth Knowing

CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) may reduce conjugated estrogen plasma levels significantly. CYP3A4 inhibitors (ketoconazole, grapefruit in large quantities) may increase estrogen exposure. Bazedoxifene is metabolized primarily by UGT enzymes (UGT1A8, UGT1A10) rather than CYP3A4, so its levels are less affected by these interactions, but the net clinical effect of the combination may still shift.

Women's Health Across Life Stages: Who Should (and Should Not) Use Duavee

Postmenopause: The Approved Population

Duavee is approved only for postmenopausal women. The SMART trials enrolled women who were at least 1 year past their final menstrual period and had an intact uterus. This is the population in which benefit-risk data exist.

Perimenopause

Duavee is not approved for perimenopause. Women in perimenopause are still cycling irregularly; their endogenous estrogen levels fluctuate and are not uniformly low. Using Duavee in perimenopause has not been studied, and BZA has not been validated as a progestogen substitute in women who still have an active hypothalamic-pituitary-ovarian axis. If you are perimenopausal and having severe hot flashes, your options include low-dose combined oral contraceptives (if no contraindications), or standard low-dose hormone therapy with a progestogen. Discuss with your provider.

PCOS Connection

Women with PCOS who reach menopause may have a longer history of anovulation and have sometimes experienced years of unopposed estrogen, raising cumulative endometrial risk. For postmenopausal women with a PCOS history, Duavee's reliable endometrial protection without progestogen intolerance is relevant. No PCOS-specific subgroup data from the SMART trials exist, so this is an extrapolation from the general postmenopausal population.

Women Who Have Had a Hysterectomy

If you have had a hysterectomy (surgical removal of the uterus), you do not need endometrial protection. Estrogen-only therapy is the standard of care for you. Duavee's primary advantage, which is replacing progestogen, does not apply. Estrogen-only Premarin or estradiol alone is simpler, less expensive, and better studied in your situation.

Pregnancy and Lactation: A Required Safety Section

Duavee is contraindicated in pregnancy.

This is non-negotiable. Conjugated estrogens and bazedoxifene are both classified as contraindicated in pregnancy. Exogenous estrogens given during organogenesis have been associated with congenital malformations in animal models, and bazedoxifene specifically has demonstrated embryo-fetal lethality and developmental toxicity in reproductive animal studies. The FDA label categorically states that Duavee should not be used during pregnancy.

Because Duavee is indicated only for postmenopausal women, the practical risk of pregnancy exposure is low. However, menopause is a clinical diagnosis that should be confirmed. Women in the menopausal transition who are not yet 12 months past their last menstrual period can still conceive and must not use Duavee.

Lactation: Estrogens are known to reduce milk production and are excreted into breast milk. Duavee should not be used by women who are breastfeeding. Given the postmenopausal indication, lactation is an extremely unlikely scenario, but the warning exists in the label.

Contraception note: Because Duavee is not a contraceptive, women who are using it and who are not yet confirmed postmenopausal (if used off-label in perimenopause, which is not approved) would need a separate non-hormonal or barrier contraceptive method. For confirmed postmenopausal women, contraception is not required.

Side Effects and Safety Monitoring

Common Side Effects

In the SMART trials, the most common adverse events in women taking CE 0.45 mg / BZA 20 mg included muscle spasms (reported in approximately 6% of participants), nausea, diarrhea, and upper abdominal discomfort. Hot flash frequency actually decreased significantly, confirming efficacy. Vaginal discharge was less common than with estrogen-only therapy.

Venous Thromboembolism Risk

Oral estrogens increase VTE risk by increasing hepatic clotting factor synthesis. In the SMART trials, VTE events were infrequent but numerically higher in active treatment groups. The absolute risk remains low in healthy postmenopausal women under 60 with no prior VTE history, but women with factor V Leiden, prior DVT, or prolonged immobility should discuss this risk explicitly with their provider. Transdermal estradiol (patches, gels, sprays) largely bypasses first-pass hepatic metabolism and carries a lower VTE signal than oral estrogen, which is a trade-off worth discussing if VTE risk is a concern.

Gallbladder Disease

Oral estrogen increases biliary cholesterol saturation and gallstone risk. Women with a prior history of gallstones or symptomatic gallbladder disease should weigh this risk carefully before starting any oral estrogen preparation, including Duavee.

Breast Monitoring

Annual mammography remains appropriate for all women on any hormone therapy, including Duavee. The SMART-5 mammographic density data are reassuring but do not replace routine screening. The American College of Obstetricians and Gynecologists recommends continuing age-appropriate breast cancer screening while on HRT.

Cardiovascular Risk

The CE component carries a class-wide cardiovascular risk warning based on data extrapolated from the WHI, which used CE 0.625 mg (a higher dose) combined with medroxyprogesterone acetate. The Menopause Society's 2023 position statement notes that for healthy women aged 50 to 59 or within 10 years of menopause onset, hormone therapy does not increase cardiovascular risk and may reduce it. This timing hypothesis has not been tested in a dedicated trial for CE/BZA specifically, so a degree of extrapolation applies.

Duavee vs. Other Menopause Hormone Therapy Options: A Practical Comparison

| Feature | Duavee (CE/BZA) | Standard Combined HRT (CE or E2 + progestogen) | Estrogen-Only (CE or E2) | |---|---|---|---| | Uterus required? | Yes (BZA protects endometrium) | Yes (progestogen protects endometrium) | No (only for women post-hysterectomy) | | Progestogen needed? | No | Yes | No | | Hot flash efficacy | Strong (SMART-2 ~74% reduction) | Strong | Strong | | Bone protection | Yes (SMART-1 BMD data) | Yes | Yes | | Mammographic density | Neutral (SMART-5) | May increase with progestogen | Neutral | | Breast cancer long-term data | Limited | Yes (WHI; modestly elevated with E+P) | Yes (WHI; no increase with CE alone) | | Route | Oral only | Oral or transdermal | Oral or transdermal | | Cost | Brand only; no generic | Generics available | Generics available | | VTE risk | Higher than transdermal | Higher than transdermal | Higher than transdermal (oral) |

Who Is a Good Candidate for Duavee and Who Is Not

Strong Candidates

You may be a strong candidate for Duavee if you are:

• Postmenopausal with an intact uterus
• Experiencing moderate-to-severe hot flashes or night sweats that are affecting sleep or quality of life
• At elevated risk for osteoporosis (low BMD on DEXA, strong family history, prior fragility fracture)
• Intolerant of progestogens due to mood changes, bloating, or breast tenderness
• Concerned about mammographic density increases associated with standard combined therapy

Who Should Not Use Duavee

Duavee is not appropriate if you have:

• A prior history of breast cancer or are at very high breast cancer risk (BRCA1/2 carrier with intact breast tissue); consult a breast oncologist before any estrogen use
• A personal history of VTE, pulmonary embolism, or known thrombophilia
• Active liver disease or unexplained elevated liver enzymes
• Undiagnosed abnormal uterine bleeding
• A history of estrogen-dependent endometrial cancer
• Confirmed pregnancy or any possibility of pregnancy
• Had a hysterectomy (simpler estrogen-only options exist for you)

The Evidence Gap: What We Do Not Yet Know

Women have historically been underrepresented in cardiovascular and oncology endpoint trials, and Duavee is no exception. The SMART program was powered for surrogate endpoints (BMD, endometrial histology, mammographic density) rather than hard clinical outcomes like fracture rates, myocardial infarction incidence, or breast cancer diagnosis over 10 to 20 years.

What is directly studied: endometrial safety, BMD change, hot flash frequency, mammographic density, and short-term safety up to 2 years.

What is extrapolated: long-term fracture prevention (inferred from BMD data), long-term breast cancer risk (inferred from SMART-5 density data and biological plausibility from BZA's receptor antagonism in breast tissue), and cardiovascular risk (extrapolated from WHI and general estrogen pharmacology).

This is not a reason to avoid Duavee; it is a reason to have an informed conversation with your provider about what is proven versus inferred, and to revisit that conversation annually.